Title Page
Contents
Abstract 7
INTRODUCTION 9
METHODS 10
RESULTS 13
DISCUSSION 17
REFERENCES 22
요약 46
Table 1. p16 staining conditions used in this study 26
Table 2. Baseline characteristics of all OPSCC patients (N=134) 26
Table 3. Baseline characteristics of OPSCC patients categorized by p16 (N=124) 27
Table 4. The distribution of staging in OPSCC patients classified according to AJCC 7th edition staging and AJCC 8th edition staging 28
Table 5. Primary treatment modality for patients with OPSCC 29
Table 6. The differences in basic characteristics between the group of patients with locally advanced OPSCC who received definitive CCRT and the group who received CCRT... 30
Table 7. Treatment outcomes according to TNM stages (AJCC 7th edition) (N=134)[이미지참조] 31
Table 8. Treatment outcomes according to TNM stages (AJCC 8th edition) (N=124)[이미지참조] 31
Table 9. Differences in treatment outcomes between the definitive CCRT group and the CCRT following induction CTx group 32
Table 10. Univariate and multivariate analysis for risk factors of OS in all OPSCC patients. 33
Table 11. Univariate and multivariate analysis for risk factors of OS in p16-positive OPSCC patients. 35
Table 12. Univariate and multivariate analysis for risk factors of OS in p16-negative OPSCC patients. 36
Table 13. Univariate and multivariate analyses of risk factors in OPSCC patients initially treated with CCRT based on cisplatin (Definitive CCRT, CCRT following induction CTx) 38
Supplemental Table 1. Treatment outcomes according to TNM stages and p16 status (AJCC 8th edition)[이미지참조] 45
Figure 1. Kaplan-Meier curve of OS according to TNM Stages (AJCC 7th edition) 40
Figure 2. Kaplan-Meier curve of OS according to TNM Stages (AJCC 8th edition) 41
Figure 3. Kaplan-Meier curve of OS who received CCRT as the primary treatment 42
Figure 4. Kaplan-Meier curve of OS according to PNI in all OPSCC patients 43
Figure 5. The Kaplan-Meier curve for OS of patients with p16-negative OPSCC, classified into 0-1 and 2-3 points based on the scoring system (LDH, ALC, PLR) 44